cladribine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (56.00) | 18.2507 |
| 2000's | 9 (36.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Messina, J; Nethers, K; Seminario-Vidal, L | 1 |
| Bair, A; Gopaluni, S; Sanyal, S; Vajpayee, N | 1 |
| Robak, T | 1 |
| Korycka, A; Robak, T | 7 |
| Fijnheer, R; Gerrits, WB; Kluin-Nelemans, HC; Oldhoff, JM; Pasmans, SG; Van 't Wout, JW; van Dobbenburgh, OA; Van Doormaal, JJ; Verhoef, G | 1 |
| Góra-Tybor, J; Robak, T | 2 |
| Anderson, WF; Elias, AL; Pankey, LR; Reeves, JE; Robbins, BA | 1 |
| Góra-Tybor, J; Korycka, A; Robak, T | 1 |
| Beutler, E; Ellison, DJ; Figueroa, ML; Kosty, M; Lemon, RH; Piro, LD; Saven, A | 1 |
| Betticher, DC; Gratwohl, A; Pless, M; Speck, B; Tichelli, A | 1 |
| Foley, KM; Rosenblum, M; Vahdat, L; Warrell, RP; Wile, MJ; Wong, ET | 1 |
| Piro, LD; Saven, A | 1 |
| Gollard, R; Miller, WE; Piro, LD; Saven, A | 1 |
| Anastasi, J; Dann, EJ; Larson, RA | 1 |
| Geisen, F; Konwalinka, G; Schirmer, M; Tiefenthaler, M | 1 |
| Korycka, A; Lech-Marańda, E; Robak, T | 1 |
| Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Blatt, LM; Ozes, ON; Reiter, Z; Taylor, MW; Tomson, S | 1 |
2 review(s) available for cladribine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
Topics: Cladribine; Humans; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous | 1993 |
5 trial(s) available for cladribine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Cladribine therapy for systemic mastocytosis.
Topics: Adult; Aged; Antimetabolites; Biomarkers; Cladribine; Drug Eruptions; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2003 |
Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Axons; Cladribine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Motor Neurons; Neural Conduction; Peripheral Nervous System Diseases; Sural Nerve | 1994 |
High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Cladribine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1998 |
Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Cladribine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Treatment Outcome | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Staphylococcal Infections; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2002 |
18 other study(ies) available for cladribine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Eruptions; Eccrine Glands; Epithelial Cells; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaplasia; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental?
Topics: Antineoplastic Agents; Biopsy; Cladribine; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Colony-Forming Units Assay; Cyclosporine; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Vidarabine | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
The influence of 2-chlorodeoxyadenosine (2-CdA) alone and in combination with cyclophosphamide or methotrexate on normal and leukemic hematopoiesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Cyclophosphamide; Hematopoiesis; Humans; Leukemia L1210; Leukemia P388; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice | 1994 |
The simultaneous occurrence of variant hairy cell leukemia and chronic-phase chronic myelogenous leukemia. A case report.
Topics: Aged; Aged, 80 and over; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Neoplasms, Second Primary; Splenectomy | 1995 |
The interaction of 2-chlorodeoxyadenosine (2-CDA) and interferon alpha (IFN-alpha) on normal and myeloid leukemia hematopoiesis in vitro.
Topics: Adult; Aged; Cladribine; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Hematopoiesis; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Recombinant Proteins | 1994 |
Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow; Cladribine; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Remission Induction | 1994 |
2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease.
Topics: Acute Disease; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Cladribine; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1994 |
The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cladribine; Drug Synergism; Granulocytes; Hematopoietic Stem Cells; Humans; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Macrophages; Middle Aged; Neoplastic Stem Cells; Recombinant Proteins | 1996 |
Interaction of 2-chlorodeoxyadenosine in combination either with interferons or recombinant human tumor necrosis factor alpha on myeloid progenitor cells in vitro.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cell Division; Cladribine; Drug Synergism; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1996 |
The influence of recombinant human tumor necrosis factor alpha and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro.
Topics: Acute Disease; Antigens, CD; Antimetabolites, Antineoplastic; Bone Marrow; Cladribine; Drug Synergism; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Neoplastic Stem Cells; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Recombinant Proteins; Structure-Activity Relationship; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Stem Cell Assay | 1997 |
2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Cladribine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 1997 |
Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Cells; Bone Marrow Purging; Cells, Cultured; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells | 1999 |
Amifostine and 2-CdA: a novel purging strategy in CML autografting?
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Bone Marrow Purging; Cladribine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm Transplantation; Radiation-Protective Agents; Transplantation, Autologous | 2000 |
The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro.
Topics: Adult; Aged; Amifostine; Cladribine; Colony-Forming Units Assay; Drug Interactions; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Middle Aged | 2000 |
Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cell Division; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Stem Cells | 2000 |
A dual anti-tumor effect of a combination of interferon-alpha and 5-flurouracil or 2-chlorodeoxyadenosine on natural killer (NK) cell mediated cytotoxicity.
Topics: 2-Chloroadenosine; Acquired Immunodeficiency Syndrome; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Cladribine; Cytotoxicity, Immunologic; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Humans; Interferon Type I; Killer Cells, Natural; Kinetics; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins; Sarcoma, Kaposi; Uterine Cervical Neoplasms | 1991 |